Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain

NeuroImage

Volumn 84, Issue , 2014, Pages 342-353

  Finnema, Sjoerd J ^a   Stepanov, Vladimir ^a   Ettrup, Anders ^b   Nakao, Ryuji ^a   Amini, Nahid ^a   Svedberg, Marie ^a   Lehmann, Charlotte ^b   Hansen, Martin ^b   Knudsen, Gitte M ^b   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

5 HT2A; 5 HT2C; 11C Cimbi 36; Agonist; Monkey; Serotonin receptors

Indexed keywords

2 (4 BROMO 2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYL)ETHANAMINE C 11; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; KETANSERIN; RADIOISOTOPE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN; VOLINANSERIN C 11; BENZYLAMINE DERIVATIVE; CARBON; CIMBI-36; PHENETHYLAMINE DERIVATIVE; SEROTONIN 2 AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN MAPPING; CHOROID PLEXUS; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; IN VITRO STUDY; MATHEMATICAL MODEL; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; RECEPTOR AFFINITY; RECEPTOR BINDING; RHESUS MONKEY; ANIMAL; BIOLOGICAL MODEL; BRAIN; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; DIAGNOSTIC USE; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; MOLECULAR IMAGING; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALS; BENZYLAMINES; BRAIN; CARBON RADIOISOTOPES; COMPUTER SIMULATION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MACACA MULATTA; METABOLIC CLEARANCE RATE; MODELS, NEUROLOGICAL; MOLECULAR IMAGING; PHENETHYLAMINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TISSUE DISTRIBUTION;

EID: 84884385086     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.08.035     Document Type: Article

References (65)

1. Adams K.H., Hansen E.S., Pinborg L.H., Hasselbalch S.G., Svarer C., Holm S., Bolwig T.G., Knudsen G.M. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int. J. Neuropsychopharmacol. 2005, 8(3):391-401.
2. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, 19:716-723.
3. Andersson J., Truong P., Halldin C. In-target produced [11C]methane: increased specific radioactivity. Appl. Radiat. Isot. 2009, 67(1):106-110.
4. Andersson J.D., Varnas K., Cselenyi Z., Gulyas B., Wensbo D., Finnema S.J., Swahn B.M., Svensson S., Nyberg S., Farde L., Halldin C. Radiosynthesis of the candidate beta-amyloid radioligand [(11)C]AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse 2010, 64(10):733-741.
5. Biver F., Goldman S., Luxen A., Monclus M., Forestini M., Mendlewicz J., Lotstra F. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur. J. Nucl. Med. 1994, 21(9):937-946.
6. Bromidge S.M., Duckworth M., Forbes I.T., Ham P., King F.D., Thewlis K.M., Blaney F.E., Naylor C.B., Blackburn T.P., Kennett G.A., Wood M.D., Clarke S.E. 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist. J. Med. Chem. 1997, 40(22):3494-3496.
7. Carson R.E. Parameter estimation in PET. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart 1986, 287-346. Raven Press, New York, USA. M.J.M. Phelps, H. Schelbert (Eds.).
8. Erritzoe D., Frokjaer V.G., Haugbol S., Marner L., Svarer C., Holst K., Baare W.F., Rasmussen P.M., Madsen J., Paulson O.B., Knudsen G.M. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. NeuroImage 2009, 46(1):23-30.
9. Ettrup A., Palner M., Gillings N., Santini M.A., Hansen M., Kornum B.R., Rasmussen L.K., Nagren K., Madsen J., Begtrup M., Knudsen G.M. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J. Nucl. Med. 2010, 51(11):1763-1770.
10. Ettrup A., Hansen M., Santini M.A., Paine J., Gillings N., Palner M., Lehel S., Herth M.M., Madsen J., Kristensen J., Begtrup M., Knudsen G.M. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur. J. Nucl. Med. Mol. Imaging 2011, 38(4):681-693.
11. Ettrup A., Holm S., Hansen M., Wasim M., Santini M.A., Palner M., Madsen J., Svarer C., Kristensen J.L., Knudsen G.M. Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [(11)C]Cimbi-36. Mol. Imaging Biol. 2013, 15(4):376-383.
12. Finnema S.J., Varrone A., Hwang T.J., Gulyas B., Pierson M.E., Halldin C., Farde L. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain. Synapse 2010, 64(7):573-577.
13. Finnema S.J., Ettrup A., Stepanov V., Nakao R., Yamamoto S., Varrone A., Knudsen G., Halldin C. Pilot study on receptor binding and serotonin sensitivity of [11C]CIMBI-36 in monkey brain. J. Nucl. Med. 2011, 52(S1):495.
14. Fitzgerald L.W., Conklin D.S., Krause C.M., Marshall A.P., Patterson J.P., Tran D.P., Iyer G., Kostich W.A., Largent B.L., Hartig P.R. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J. Neurochem. 1999, 72(5):2127-2134.
15. Garber J.C., Barbee R.W., Bielitzki J.T., Clayton L.A., Donovan J.C., Hendriksen C.F.M., Kohn D.F., Lipman N.S., Locker P.A., Melcher J., Quimby F.W., Turner P.V., Wood G.A., Wurbel H. Guide for the Care and Use of Laboratory Animals 2011, The National Academies Press, Washington D.C., USA.
16. Ginovart N., Galineau L., Willeit M., Mizrahi R., Bloomfield P.M., Seeman P., Houle S., Kapur S., Wilson A.A. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 2006, 97(4):1089-1103.
17. Granda M.L., Carlin S.M., Moseley C.K., Neelamegam R., Mandeville J.B., Hooker J.M. Synthesis and evaluation of methylated arylazepine compounds for PET imaging of 5-HT(2c) receptors. ACS Chem. Neurosci. 2013, 4(2):261-265.
18. Hall H., Farde L., Halldin C., Lundkvist C., Sedvall G. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 2000, 38(4):421-431.
19. Hansen H.D., Ettrup A., Herth M.M., Dyssegaard A., Ratner C., Gillings N., Knudsen G.M. Direct comparison of [(18) F]MH.MZ and [(18) F]altanserin for 5-HT2A receptor imaging with PET. Synapse 2013, 67(6):328-337.
20. Haugbol S., Pinborg L.H., Regeur L., Hansen E.S., Bolwig T.G., Nielsen F.A., Svarer C., Skovgaard L.T., Knudsen G.M. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int. J. Neuropsychopharmacol. 2007, 10(2):245-252.
21. Hirani E., Sharp T., Sprakes M., Grasby P., Hume S. Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies. Synapse 2003, 50(3):251-260.
22. Hoyer D., Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36(4-5):419-428.
23. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27(9):1533-1539.
24. Ito H., Nyberg S., Halldin C., Lundkvist C., Farde L. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J. Nucl. Med. 1998, 39(1):208-214.
25. Johnson M.P., Siegel B.W., Carr A.A. [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 354(2):205-209.
26. Karlsson P., Farde L., Halldin C., Swahn C.G., Sedvall G., Foged C., Hansen K.T., Skrumsager B. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl.) 1993, 113(2):149-156.
27. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997, 36(4-5):609-620.
28. Kent R.S., De Lean A., Lefkowitz R.J. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol. Pharmacol. 1980, 17(1):14-23.
29. Knight A.R., Misra A., Quirk K., Benwell K., Revell D., Kennett G., Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370(2):114-123.
30. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4(3 Pt 1):153-158.
31. Lemaire C., Cantineau R., Guillaume M., Plenevaux A., Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J. Nucl. Med. 1991, 32(12):2266-2272.
32. Leysen J.E., Awouters F., Kennis L., Laduron P.M., Vandenberk J., Janssen P.A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981, 28(9):1015-1022.
33. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10(5):740-747.
34. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16(5):834-840.
35. Loo H., Hale A., D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17(5):239-247.
36. Lopez-Gimenez J.F., Vilaro M.T., Palacios J.M., Mengod G. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 1998, 37(9):1147-1158.
37. Lopez-Gimenez J.F., Mengod G., Palacios J.M., Vilaro M.T. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 2001, 42(1):12-26.
38. Lopez-Gimenez J.F., Vilaro M.T., Palacios J.M., Mengod G. Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies. J. Comp. Neurol. 2001, 429(4):571-589.
39. Lopez-Gimenez J.F., Villazon M., Brea J., Loza M.I., Palacios J.M., Mengod G., Vilaro M.T. Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. Mol. Pharmacol. 2001, 60(4):690-699.
40. Lundkvist C., Halldin C., Ginovart N., Nyberg S., Swahn C.G., Carr A.A., Brunner F., Farde L. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci. 1996, 58(10):PL 187-PL 192.
41. Manvich D.F., Kimmel H.L., Cooper D.A., Howell L.L. The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys. J. Pharmacol. Exp. Ther. 2012, 342(3):761-769.
42. Manvich D.F., Kimmel H.L., Howell L.L. Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 2012, 341(2):424-434.
43. Marazziti D., Rossi A., Palego L., Giannaccini G., Naccarato A., Lucacchini A., Cassano G.B. [3H]ketanserin binding in human brain postmortem. Neurochem. Res. 1997, 22(6):753-757.
44. Marazziti D., Rossi A., Giannaccini G., Zavaglia K.M., Dell'Osso L., Lucacchini A., Cassano G.B. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur. Neuropsychopharmacol. 1999, 10(1):21-26.
45. Milak M.S., Severance A.J., Prabhakaran J., Kumar J.S., Majo V.J., Ogden R.T., Mann J.J., Parsey R.V. In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer. J. Cereb. Blood Flow Metab. 2011, 31(1):243-249.
46. Millan M.J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., Rivet J.M., Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003, 306(3):954-964.
47. Narendran R., Hwang D.R., Slifstein M., Talbot P.S., Erritzoe D., Huang Y., Cooper T.B., Martinez D., Kegeles L.S., Abi-Dargham A., Laruelle M. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 2004, 52(3):188-208.
48. Narendran R., Mason N.S., Laymon C.M., Lopresti B.J., Velasquez N.D., May M.A., Kendro S., Martinez D., Mathis C.A., Frankle W.G. A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J. Pharmacol. Exp. Ther. 2010, 333(2):533-539.
49. Nord M., Finnema S.J., Halldin C., Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int. J. Neuropsychopharmacol. 2013, 1-10.
50. Parker C.A., Gunn R.N., Rabiner E.A., Slifstein M., Comley R., Salinas C., Johnson C.N., Jakobsen S., Houle S., Laruelle M., Cunningham V.J., Martarello L. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J. Nucl. Med. 2012, 53(2):295-303.
51. Paterson L.M., Kornum B.R., Nutt D.J., Pike V.W., Knudsen G.M. 5-HT radioligands for human brain imaging with PET and SPECT. Med. Res. Rev. 2013, 33(1):54-111.
52. 18F]altanserin-PET and the bolus/infusion approach. J. Cereb. Blood Flow Metab. 2003, 23(8):985-996.
53. Pinborg L.H., Adams K.H., Yndgaard S., Hasselbalch S.G., Holm S., Kristiansen H., Paulson O.B., Knudsen G.M. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge. J. Cereb. Blood Flow Metab. 2004, 24(9):1037-1045.
54. Quednow B.B., Treyer V., Hasler F., Dorig N., Wyss M.T., Burger C., Rentsch K.M., Westera G., Schubiger P.A., Buck A., Vollenweider F.X. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. NeuroImage 2012, 59(4):3922-3932.
55. Saleem K.S., Logothesis N.K. A combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates 2007, Academic Press, Oxford, U.K.
56. Selvaraj S., Turkheimer F., Rosso L., Faulkner P., Mouchlianitis E., Roiser J.P., McGuire P., Cowen P.J., Howes O. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol. Psychiatry 2012, 17(12):1254-1260.
57. Seneca N., Finnema S.J., Farde L., Gulyas B., Wikstrom H.V., Halldin C., Innis R.B. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 2006, 59(5):260-269.
58. Shotbolt P., Tziortzi A.C., Searle G.E., Colasanti A., van der Aart J., Abanades S., Plisson C., Miller S.R., Huiban M., Beaver J.D., Gunn R.N., Laruelle M., Rabiner E.A. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J. Cereb. Blood Flow Metab. 2012, 32(1):127-136.
59. Slifstein M., Parsey R.V., Laruelle M. Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl. Med. Biol. 2000, 27(5):487-492.
60. Smith B.M., Smith J.M., Tsai J.H., Schultz J.A., Gilson C.A., Estrada S.A., Chen R.R., Park D.M., Prieto E.B., Gallardo C.S., Sengupta D., Dosa P.I., Covel J.A., Ren A., Webb R.R., Beeley N.R., Martin M., Morgan M., Espitia S., Saldana H.R., Bjenning C., Whelan K.T., Grottick A.J., Menzaghi F., Thomsen W.J. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J. Med. Chem. 2008, 51(2):305-313.
61. Song J., Hanniford D., Doucette C., Graham E., Poole M.F., Ting A., Sherf B., Harrington J., Brunden K., Stricker-Krongrad A. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. Assay Drug Dev. Technol. 2005, 3(6):649-659.
62. Staley J.K., Van Dyck C.H., Tan P.Z., Al Tikriti M., Ramsby Q., Klump H., Ng C., Garg P., Soufer R., Baldwin R.M., Innis R.B. Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. Nucl. Med. Biol. 2001, 28(3):271-279.
63. Talbot P.S., Slifstein M., Hwang D.R., Huang Y., Scher E., Abi-Dargham A., Laruelle M. Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone. NeuroImage 2012, 59(1):271-285.
64. Thomsen W.J., Grottick A.J., Menzaghi F., Reyes-Saldana H., Espitia S., Yuskin D., Whelan K., Martin M., Morgan M., Chen W., Al-Shamma H., Smith B., Chalmers D., Behan D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 2008, 325(2):577-587.
65. Varrone A., Sjoholm N., Eriksson L., Gulyas B., Halldin C., Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(10):1639-1650.